HC Wainwright Has Negative Estimate for Evotec Q3 Earnings

Evotec AG (NASDAQ:EVO) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Evotec in a report issued on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.31) EPS and FY2027 earnings at $0.07 EPS.

EVO has been the topic of several other reports. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research report on Wednesday. Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Weiss Ratings raised Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $3.00.

Evotec Stock Down 0.5%

NASDAQ EVO opened at $1.96 on Friday. The stock has a 50 day moving average price of $2.75 and a 200-day moving average price of $3.01. The company has a current ratio of 1.68, a quick ratio of 1.60 and a debt-to-equity ratio of 0.43. Evotec has a one year low of $1.95 and a one year high of $4.42.

Institutional Trading of Evotec

A number of large investors have recently made changes to their positions in EVO. Apollon Wealth Management LLC purchased a new position in Evotec in the first quarter worth approximately $28,000. Marshall Wace LLP purchased a new stake in shares of Evotec in the 4th quarter valued at approximately $40,000. SmartHarvest Portfolios LLC purchased a new stake in shares of Evotec in the 1st quarter valued at approximately $44,000. BNP Paribas Financial Markets raised its holdings in shares of Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec News Summary

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.